SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. BIORthe biotech company reinventing therapeutics announced today that the United States Patent and Trademark Office (USPTO) has granted a patent related to the company’s technologies for oral, systemic delivery of biologics involving an ingestible device designed for systemic uptake liquid jet delivery to the small intestine.

The USPTO issued U.S. Patent No. 11,439,802 entitled “Ingestible Device for Delivery of a Therapeutic Agent to the Gastrointestinal Tract”. The patent relates to methods of using an ingestible device to treat a disease or condition in a patient using jet administration of a glucagon receptor agonist (RA) or glucagon-like peptide-1 (GLP-1) receptor Agonist formulation to the small intestine to achieve systemic uptake.

GLP-1 receptor agonists are a class of drugs that are approved for type 2 diabetes and weight loss, but are also being studied by other parties in other diseases, including fatty liver and atrial fibrillation. According to leading analytics firm GlobalData, the GLP-1 receptor agonist market is projected to be well over $20 billion by 2025, with multi-billion dollar drugs including Victoza^®truth^®Ozempic^®Rybelsus^®and Mounjaro^®.

“This latest patent is important to us because it generally covers oral administration of any GLP-1 RA using an ingestible device and jet delivery to the small intestine,” said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. “It strengthens the intellectual property position for our PGN-OB2 candidate, which consists of a GLP-1 receptor agonist injected into small intestinal tissue for the treatment of type 2 diabetes,” continued Mr. Mohanty. “The only oral GLP-1 receptor agonist available today has a bioavailability of approximately 1%. We believe we can do significantly better as we have already demonstrated preclinical bioavailability averaging over 20% with proteins.”

While…